ALK and non-small cell lung carcinoma: The results of crizotinib in the first-line setting of patients with ALK-positive NSCLC made clear the benefit and superiority of the targeted treatment in comparison with chemotherapy, although the overall survival was not significantly different due to the effect of the cross-over permitted in the PROFILE 1014 trial [8], with the issue of the brain confirming pharmacokinetic resistance, as shown by the crizotinib concentration in the CSF [10,11].